Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin
- 1 May 1990
- journal article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 31 (3) , 182-186
- https://doi.org/10.1007/bf01744734
Abstract
Urine samples were obtained from patients with superficial bladder cancer after immunotherapy with bacillus Calmette-Guérin (BCG). The patients were repeatedly (once a week for 6 consecutive weeks) treated with intravesical administration of approximately 5 × 108 culturable particles of BCG. Some patients received more than six BCG instillations. The urine samples were investigated for the presence of interleukin-2 (IL-2) in an in vitro bioassay using a murine cytotoxic T cell line (CTTL-16) that shows IL-2-dependent growth. Preliminary experiments indicated the presence of inhibitory factors in the urine. This inhibitory activity was abolished after 24 h dialysis. In a neutralization assay with both polyvalent and monoclonal anti-(human IL-2) antibody it was demonstrated that there was indeed IL-2 in the urine samples. In 8 of 11 patients the presence of IL-2 in the urine was demonstrated. The IL-2 production was directly related to the BCG administration as samples obtained just before the BCG instillation were always negative. In IL-2-positive samples a maximum level of IL-2 was observed between 2 h and 6 h after the BCG instillation. In urine samples obtained 24 h after the BCG IL-2 was not detected. In most patients the urine became positive after the third or fourth BCG instillationKeywords
This publication has 28 references indexed in Scilit:
- Immunotherapy of cancer using interleukin 2: current status and future prospectsImmunology Today, 1988
- Histological evaluation of immunologically mediated tumor regression of the line 10 guinea pig hepatocarcinomaVirchows Archiv B Cell Pathology Including Molecular Pathology, 1986
- Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: Lack of a role of natural killer cellsClinical Immunology and Immunopathology, 1986
- Histopathology of BCG and thiotepa treated bladdersUrological Research, 1986
- Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancerClinical Immunology and Immunopathology, 1986
- Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary reportInternational Journal of Cancer, 1984
- T-cell growth factors: interleukin 2Immunology Today, 1980
- Modulation of immunity by bacillus calmette-guérin (BCG)Pharmacology & Therapeutics, 1979